Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alfuzosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.49 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.49 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.31 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alfuzosin SCHEMBL8109775 | 0.97 | ADRA1D (0.46) | ADRA1DADRA1AADRA1BKDM4EALDH1A1 | |
| Alfuzosin SCHEMBL8105867 | 0.95 | ADRA1D (0.53) | ADRA1DADRA1AADRA1BKDM4EALDH1A1 | |
| Alfuzosin SCHEMBL8094025 | 0.92 | ALDH1A1 (0.58) | ADRA1DADRA1AADRA1BKDM4EALDH1A1 | |
| Alfuzosin SCHEMBL8109753 | 0.91 | ADRA1D (0.60) | ADRA1DADRA1AADRA1BKDM4EALDH1A1 | |
| Alfuzosin SCHEMBL8103438 | 0.89 | ALDH1A1 (0.54) | ADRA1DADRA1AADRA1BKDM4EALDH1A1 | |
| Alfuzosin SCHEMBL8107464 | 0.88 | ADRA1D (0.61) | ADRA1DADRA1AADRA1BKDM4EALDH1A1 | |
| Alfuzosin SCHEMBL8103791 | 0.88 | ADRA1D (0.56) | ADRA1DADRA1AADRA1BKDM4EALDH1A1 | |
| Alfuzosin SCHEMBL8097945 | 0.87 | KDM4E (0.42) | ADRA1DADRA1AADRA1BKDM4EALDH1A1 | |
| Alfuzosin SCHEMBL8108092 | 0.87 | ALDH1A1 (0.61) | ADRA1DADRA1AADRA1BKDM4EALDH1A1 | |
| Alfuzosin SCHEMBL8107473 | 0.87 | ADRA1D (0.66) | ADRA1DADRA1AADRA1BKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039473-A1 | PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039473-A1 | PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS | ADRB1, ADRB2, ADRB3 | ADRA1D 9/4885ADRA1A 8/4885ADRA1B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.